With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...
An even greater share of the active pharmaceutical ingredients, or APIs, used in drugs comes from abroad: around 80%, he said. China is increasingly playing ... Rena Conti, an associate professor at ...
Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China Department of Medicinal Chemistry, School ...
China Resources Pharmaceutical Group (CR Pharmaceutical ... drug after findings from a preclinical research project at the University of Hong Kong showed a close association between Alzheimer ...
Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China ...
including the aviation composite materials R&D and manufacturing base of the China National Building Material Group Co Ltd, Qilu Pharmaceutical's global R&D headquarters for drug innovation ...
Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...
We would like to thank professor Wenxi Tang of China Pharmaceutical University for her guidance on the direction of the application of system dynamics in health policy. We would like to thank China’s ...
2 State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China 3 Department of Integration of Chinese and Western Medicine, School of ...
FDA slaps China-based API makers with separate warning letters outlining quality, testing shortfalls
A pair of Chinese manufacturers with active pharmaceutical ingredients that were previously shipped to the U.S. | The FDA ...
President Trump’s tariffs in China are in place and hitting all products imported from the country — including a number of pharmaceutical drugs that Americans rely upon. Chinese imports ...
China's healthcare regulator on Sunday defended the efficacy of off-patent medicines it had approved to be distributed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results